The protective role of polymorphism MKK4-1304 T>G in nasopharyngeal carcinoma is modulated by Epstein-Barr virus' infection status

International Journal of Cancer

Volumn 130, Issue 9, 2012, Pages 1981-1990

  Zheng, Jian ^a   Liu, Bin ^b   Zhang, Liyuan ^a   Jiang, Lan ^a   Huang, Binfang ^b   You, Yonghe ^a   Jiang, Qingping ^b   Zhang, Shuxu ^b   Lu, Jiachun ^b   Zhou, Yifeng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Epstein Barr virus; MKK4; nasopharyngeal carcinoma; polymorphisms

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MKK4 GENE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTECTION; RISK REDUCTION;

ADULT; AGED; CASE-CONTROL STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MAP KINASE KINASE 4; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84857504499     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26253     Document Type: Article

References (33)

1. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010; 42: 599-603.
2. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K,. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res 2009; 143: 209-21.
3. Cho WC,. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007; 6: 1.
4. Pattle SB, Farrell PJ,. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 2006; 6: 1193-205.
5. Zheng H, Li LL, Hu DS, Deng XY, Cao Y,. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 2007; 4: 185-96.
6. Morris MA, Dawson CW, Young LS,. Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol 2009; 5: 811-25.
7. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP,. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 473-87.
8. Kutz H, Reisbach G, Schultheiss U, Kieser A,. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. Virology 2008; 371: 246-56.
9. Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS,. Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J Virol 2008; 82: 3654-64.
10. Chen CC, Chen LC, Liang Y, Tsang NM, Chang YS,. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways. Cell Signal 2010; 22: 1132-42.
11. Li L, Guo L, Tao Y, Zhou S, Wang Z, Luo W, Hu D, Li Z, Xiao L, Tang M, Yi W, Tsao SW, et al. Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett 2007; 255: 219-31.
12. Chang SH, Chang HC, Hung WC,. Transcriptional repression of tissue inhibitor of metalloproteinase-3 by Epstein-Barr virus latent membrane protein 1 enhances invasiveness of nasopharyngeal carcinoma cells. Oral Oncol 2008; 44: 891-7.
13. Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, Tsao SW, Tse KP, Yu JS, Chang YS,. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 2006; 66: 11668-76.
14. Niemhom S, Kitazawa S, Kitazawa R, Maeda S, Leopairat J,. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detect Prev 2008; 32: 127-34.
15. Zou H, Li Q, Lin SC, Wu Z, Han J, Ye Z,. Differential requirement of MKK4 and MKK7 in JNK activation by distinct scaffold proteins. FEBS Lett 2007; 581: 196-202.
16. Finegan KG, Tournier C,. The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res 2010; 70: 5797-806.
17. Huang C, Huang K, Wang C, Jiang ZD, Li XX, Wang HP, Chen HY,. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol Rep 2009; 22: 89-95.
18. Teng DH, Perry WL III, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57: 4177-82.
19. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH, Kern SE,. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998; 58: 2339-42.
20. Chae KS, Ryu BK, Lee MG, Byun DS, Chi SG,. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma. Eur J Cancer 2002; 38: 2048-57.
21. Su GH, Song JJ, Repasky EA, Schutte M, Kern SE,. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat 2002; 19: 81.
22. Whitmarsh AJ, Davis RJ,. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 2007; 26: 3172-84.
23. Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS,. The role of metastasis suppressor genes in metastatic dormancy. APMIS 2008; 116: 586-601.
24. Wei Y, Wang L, Lan P, Zhao H, Pan Z, Huang J, Lu J, Wang J,. The association between -1304T>G polymorphism in the promoter of MKK4 gene and the risk of sporadic colorectal cancer in southern Chinese population. Int J Cancer 2009; 125: 1876-83.
25. Liu B, Chen D, Yang L, Li Y, Ling X, Liu L, Ji W, Wei Y, Wang J, Wei Q, Wang L, Lu J,. A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity. Carcinogenesis 2010; 31: 1405-11.
26. Jiang L, Zhang C, Li Y, Yu X, Zheng J, Zou P, Bin X, Lu J, Zhou Y,. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat 2010.
27. Lehmann U, Kreipe H,. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001; 25: 409-18.
28. Lu J, Wang LE, Xiong P, Sturgis EM, Spitz MR, Wei Q,. 172G>T variant in the 5†untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. Carcinogenesis 2007; 28: 988-94.
29. Liu Y, Wang X, Lo AK, Wong YC, Cheung AL, Tsao SW,. Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. J Med Virol 2002; 66: 63-9.
30. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, Wang WB, Chen JY,. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004; 23: 2531-9.
31. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N,. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
32. Wakefield J,. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet 2007; 81: 208-27.
33. Cho WC,. Recent progress in genetic variants associated with cancer and their implications in diagnostics development. Expert Rev Mol Diagn 2010; 10: 699-703.